LabGenomics Appoints Pharmaceutical Marketing Expert Byungki Kim as Head of Marketing

On September 5, LabGenomics, a global leader in genomic molecular diagnostics, announced that it has appointed Byungki Kim, former Head of Product Strategy at Aju Pharm, as its new Head of Marketing. Kim brings extensive experience in sales and marketing strategy within the pharmaceutical industry.

Head of Marketing Byungki Kim has worked at leading domestic pharmaceutical companies such as Daewoong Pharmaceutical, Hanmi Pharmaceutical, Chong Kun Dang, and Aju Pharm, where he developed precise market analyses and tailored sales strategies for each indication, resulting in increased prescription sales at hospitals and clinics. He also contributed to the company's external growth by stabilizing its contract sales organization (CSO) business. In addition, he gained hands-on marketing experience in diverse market environments while working at global pharmaceutical companies such as Abbott Korea and Janssen.

In particular, Kim is recognized as an expert with a broad range of capabilities, from setting sales direction and executing detailed strategies to organizational innovation and leadership, thanks to his experience building key opinion leader (KOL) networks centered on major hospitals and extensive hospital and clinic networks at large pharmaceutical companies.

A company representative emphasized, "We believe that Head of Marketing Byungki Kim's capabilities and extensive experience in pharmaceutical marketing make him the right person to strengthen our marketing capabilities in the domestic diagnostics and consignment business, as well as to create synergy between the U.S. and Korean diagnostics markets."

Following the appointment of a CEO from the pharmaceutical industry, the company plans to further strengthen the competitiveness of its diagnostics and consignment business by bringing in a marketing expert with rich experience in the pharmaceutical sector and applying proven advanced marketing techniques to the diagnostics and consignment market. The company also plans to pursue various new businesses, such as AI diagnostics and medical devices, that can create synergy with its existing operations.

Head of Marketing Byungki Kim stated, "Going forward, the diagnostics sector is expected to grow even faster than the therapeutics market, and since both pharmaceuticals and diagnostics target healthcare professionals, including physicians, there are many commonalities that will be advantageous. I will optimize and apply proven marketing strategies from the pharmaceutical industry to LabGenomics' diagnostics and consignment business, and by collaborating with our established U.S. CLIA lab network, I aim to generate synergy to expand the diagnostics market in both Korea and the United States and achieve significant external growth."